Skip to main content

Table 4 Follow-up data

From: Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting

 

Non-Diabetic (n = 2181)

Good-control DM (n = 291)

Poor-control DM (n = 412)

P-value*

P-value†

P-value‡

Total MACE

65 (3.0)

9 (3.1)

21 (5.1)

0.85

0.09

0.33

In-hospital MACE

27 (1.2)

3 (1.0)

3 (0.7)

1.00

0.79

0.70

TVR

23 (1.1)

4 (1.4)

13 (3.2)

0.55

0.002

0.14

TLR

9 (0.4)

3 (1.0)

4 (1.0)

0.16

0.13

1.00

CABG

10 (0.4)

0 (0)

6 (1.4)

0.62

0.03

0.04

Non-fatal MI

26 (1.1)

4 (1.4)

6 (1.4)

0.77

0.62

1.00

All-cause mortality

25 (1.1)

1 (0.3)

4 (1.0)

0.35

1.00

0.41

Cardiac death

16 (0.7)

1 (0.3)

2 (0.5)

0.71

1.00

1.00

Non-cardiac death

9 (0.4)

0 (0)

2 (0.5)

0.61

0.69

0.51

  1. Data are presented as n (%).
  2. * Non-diabetic patients versus good-control (diabetic patients with HbA1c ≤ 7%).
  3. † Non-diabetic patients versus poor-control (diabetic patients with HbA1c > 7%).
  4. ‡ Good-control versus poor-control diabetic patients.
  5. CABG, coronary artery bypass grafting surgery; MACE, major adverse cardiovascular events; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization.